Opinion|Videos|January 9, 2025
Emerging Treatments for Patients with NMIBC
Author(s)Mark D. Tyson, II, M.D., M.P.H.
A panelist discusses how emerging investigational agents for NMIBC show promise through diverse mechanisms, including oncolytic viruses (CG0070), immune checkpoint inhibitors (durvalumab, sasanlimab), targeted drug delivery systems (TAR-200), mitomycin-containing gels (UGN-102/103), immunotherapies (TARA-002), gene therapies (EG-70), and FGFR inhibitors (erdafitinib), representing a robust pipeline of potential treatment options.
Advertisement
- Please give an overview and your overall impressions about selected investigational agents to treat patients with NMIBC.
- Cretostimogene grenadenorepvec (CG0070)
- Durvalumab
- Tar-200
- UGN-102 and UGN 103
- Sasanlimab
- TARA-002
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Urology Times
1
Alternative BCG strains may help address ongoing supply challenges in NMIBC
2
Doublet or triplet? Urologists weighs in on mCSPC options
3
Pearls & Perspectives: Sexual Health and Intimacy in Midlife, With Karen Bigman, MBA
4
Phase 3 trial of padeliporfin VTP completes treatment in LG-UTUC
5